These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 22013933)

  • 1. Plasma pentraxin 3 is associated with cardiovascular disease in hemodialysis patients.
    Xu Y; Ding X; Zou J; Liu Z; Jiang S; Xu S; Shen B; Chen Y; Shan Y; Cao X
    Ren Fail; 2011; 33(10):998-1004. PubMed ID: 22013933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease.
    Boehme M; Kaehne F; Kuehne A; Bernhardt W; Schröder M; Pommer W; Fischer C; Becker H; Müller C; Schindler R
    Nephrol Dial Transplant; 2007 Aug; 22(8):2224-9. PubMed ID: 17496115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of plasma pentraxin 3 and monocyte chemoattractant protein-1 concentrations with cardiovascular disease in patients with chronic kidney disease.
    Nishi K; Imamura T; Kitamura K; Ogawa T; Fujimoto S; Kakitsubata Y; Ishikawa T; Asada Y; Kodama T
    Ren Fail; 2011; 33(4):398-404. PubMed ID: 21529268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma pentraxin-3 as a marker of bioincompatibility in hemodialysis patients.
    Oldani S; Finazzi S; Bottazzi B; Garlanda C; Baldassarre E; Valaperta S; Cuccovillo I; Albini M; Child M; Montanelli A; Graziani G; Badalamenti S
    J Nephrol; 2012; 25(1):120-6. PubMed ID: 21725917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma pentraxin 3 may be a better marker of peripheral artery disease in hemodialysis patients than C-reactive protein.
    Zhou Y; Ni Z; Zhang J; Zhang W; Wu Q; Shen G; Wang Y; Qian J
    Vasc Med; 2013 Apr; 18(2):85-91. PubMed ID: 23609129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma myeloperoxidase, NT-proBNP, and troponin-I in patients on CAPD compared with those on regular hemodialysis.
    Al-Hweish A; Sultan SS; Mogazi K; Elsammak MY
    Hemodial Int; 2010 Jul; 14(3):308-15. PubMed ID: 20597992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pentraxin 3 and C-reactive protein in severe meningococcal disease.
    Sprong T; Peri G; Neeleman C; Mantovani A; Signorini S; van der Meer JW; van Deuren M
    Shock; 2009 Jan; 31(1):28-32. PubMed ID: 18650775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical value of plasma pentraxin 3 levels for predicting cardiac troponin elevation after percutaneous coronary intervention.
    Wang Z; Sato A; Akiyama D; Kimura T; Tajiri K; Hoshi T; Sakai S; Koike A; Miyauchi T; Aonuma K
    Life Sci; 2014 Jan; 95(1):40-4. PubMed ID: 24333560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure.
    Suzuki S; Takeishi Y; Niizeki T; Koyama Y; Kitahara T; Sasaki T; Sagara M; Kubota I
    Am Heart J; 2008 Jan; 155(1):75-81. PubMed ID: 18082493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction.
    Latini R; Maggioni AP; Peri G; Gonzini L; Lucci D; Mocarelli P; Vago L; Pasqualini F; Signorini S; Soldateschi D; Tarli L; Schweiger C; Fresco C; Cecere R; Tognoni G; Mantovani A;
    Circulation; 2004 Oct; 110(16):2349-54. PubMed ID: 15477419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pentraxin 3 as a biomarker for acute coronary syndrome: comparison with biomarkers for cardiac damage.
    Kume N; Mitsuoka H; Hayashida K; Tanaka M
    J Cardiol; 2011 Jul; 58(1):38-45. PubMed ID: 21616640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated plasma pentraxin 3: a potential cardiovascular risk factor?
    Liu Q; Tu T; Bai Z; Liu Z; Zhou S
    Med Hypotheses; 2011 Dec; 77(6):1068-70. PubMed ID: 21944885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD.
    Honda H; Qureshi AR; Heimbürger O; Barany P; Wang K; Pecoits-Filho R; Stenvinkel P; Lindholm B
    Am J Kidney Dis; 2006 Jan; 47(1):139-48. PubMed ID: 16377395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients.
    Afzali B; Bakri RS; Bharma-Ariza P; Lumb PJ; Dalton N; Turner NC; Wierzbicki AS; Crook MA; Goldsmith DJ
    J Nephrol; 2003; 16(4):540-5. PubMed ID: 14696756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of pentraxin 3 in patients with chronic heart failure.
    Kotooka N; Inoue T; Aoki S; Anan M; Komoda H; Node K
    Int J Cardiol; 2008 Oct; 130(1):19-22. PubMed ID: 18045709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality.
    Suliman ME; Qureshi AR; Carrero JJ; Bárány P; Yilmaz MI; Snaedal-Jonsdottir S; Alvestrand A; Heimbürger O; Lindholm B; Stenvinkel P
    QJM; 2008 May; 101(5):397-405. PubMed ID: 18292098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased serum pentraxin 3 in patients with systemic sclerosis.
    Iwata Y; Yoshizaki A; Ogawa F; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory status in patients with chronic renal failure: the role of PTX3 and pro-inflammatory cytokines.
    Malaponte G; Libra M; Bevelacqua Y; Merito P; Fatuzzo P; Rapisarda F; Cristina M; Naselli G; Stivala F; Mazzarino MC; Castellino P
    Int J Mol Med; 2007 Oct; 20(4):471-81. PubMed ID: 17786277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cardiovascular risk markers in hemodialysis].
    Urso S; Milone F; Garozzo M; Cannavò ME; Biondi A; Battaglia G
    G Ital Nefrol; 2004; 21 Suppl 30():S212-6. PubMed ID: 15750988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma concentrations of C-reactive protein and total homocysteine in relation to the severity and risk factors for cerebrovascular disease.
    Youssef MY; Mojiminiyi OA; Abdella NA
    Transl Res; 2007 Sep; 150(3):158-63. PubMed ID: 17761368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.